10655 Sorrento Valley Road
Suite 200
San Diego, CA 92121
United States
858 526 3100
https://www.histogen.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 22
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Steven J. Mento Ph.D. | Exec. Chairman, Interim Pres & CEO | 335.4k | N/A | 1952 |
Ms. Susan A. Knudson | Exec. VP, CFO, Chief Compliance Officer & Corp. Sec. | 385.25k | N/A | 1964 |
Dr. Gail K. Naughton Ph.D. | Founder & Scientific Advisor | N/A | N/A | 1956 |
Mr. Stephen Hill Jr. | VP & Controller | N/A | N/A | N/A |
Mr. Thomas L. Hubka | Director of Bus. Operations & Corp. Sec. | N/A | N/A | 1987 |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Histogen Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.